Abbott Upgrading Texas Rx Plant Following GMP Warning Letter
Executive Summary
Abbott is accelerating enhancement of the monitoring system validation program for manufacturing at its Austin, Tex. facility following receipt of an FDA warning letter
You may also be interested in...
Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending
Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira
Abbott Hospital Products Spin-Off Will Free Up $500 Mil. For Rx Spending
Abbott's planned spin-off of a new hospital products company will free up approximately $500 mil. to invest in R&D and promotional support for Humira
FDA Reinspecting Abbott Depakote ER Backup Facility After Warning Letter
FDA is reinspecting Abbott's Abbott Park, Ill. manufacturing facility as a follow-up to a warning letter citing violations of good manufacturing practices